Redx Pharma appoints Iain Ross as chairman
AIM-listed Redx Pharma has appointed Iain Ross as chairman of its board and as a non-executive director, effective from 1 May.
Ross has over 35 years' experience having held senior positions at multiple public and private life sciences companies and is vice chairman of Royal Holloway, University of London.
He is also currently non-executive chairman of AIM quoted e-Therapeutics and Biomer Technology alongside his non-executive directorships at Premier Veterinary Group, Australia-listed Anatara LifeSciences and Novogen as well as being a director of Aldershot Town Football Club.
Chief executive Dr Neil Murray said that under Ross’ “stewardship the company will deliver shareholder value as we transition into a clinical-stage research and development company with a focus on cancer, immunology and infection”.
Ross said: "Redx Pharma is a business of the highest quality that has discovered high value assets in cancer, immunology and infection and the opportunity to be part of progressing these promising assets through the clinic was instantly appealing.
Shares in Redx Pharma were down 2.44% to 35p at 0908 BST.